Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439158 | 0.91 | OPRM1 (0.52) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17439160 | 0.85 | OPRM1 (0.54) | OPRM1OPRL1CYP2C19CYP3A4TSHR | |
| SCHEMBL17438586 | 0.85 | OPRM1 (0.51) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17438955 | 0.85 | OPRM1 (0.46) | OPRM1OPRL1HSD11B1CYP2C19CYP3A4 | |
| SCHEMBL17438804 | 0.85 | OPRM1 (0.51) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17438720 | 0.84 | OPRM1 (0.69) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17438890 | 0.84 | OPRM1 (0.54) | OPRM1OPRL1CYP2C19CYP3A4TSHR | |
| SCHEMBL17438983 | 0.83 | OPRM1 (0.52) | OPRM1OPRL1HSD11B1CYP2C19CYP3A4 | |
| SCHEMBL17439060 | 0.83 | OPRM1 (0.53) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17438597 | 0.82 | OPRM1 (0.69) | OPRM1OPRL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885HSD11B1 1377/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885HSD11B1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.